PD-1 vs PD-L1 Inhibitors: Do Outcomes Differ? Meta-analysis suggests they aren't equivalent Dec 27, 2019
Pembrolizumab Shows Survival Benefit in KRAS-Mutant NSCLC Improved OS, PFS, and response rates compared to chemo in first-line Dec 16, 2019
AHA Dedicates $20 Million to Youth Vaping Research Association and partners aim to "hold e-cigarette companies publicly accountable for their lies" Nov 16, 2019
Rheumatoid Arthritis Is No Bar to Cancer Immunotherapy Small study finds flares common with checkpoint inhibitors, but few patients stopped treatment because of them Nov 13, 2019
Notable OS Gains with Dual Immunotherapy in Advanced NSCLC Secondary analysis of CheckMate 227 brings more good news for nivolumab-ipilimumab combo Sep 28, 2019
BCG Vax: A Shot Against Lung Cancer in Native Populations? 60-year follow-up data from a vaccine trial found surprising results Sep 25, 2019
Post-Immunotherapy SBRT Boosts Outcomes in Advanced NSCLC Increased systemic response rate, disease control rate, and PFS in phase II trial Sep 17, 2019
Anti-PD-1/L1 for NSCLC Sparks Talk of the 'C' Word Unprecedented survival at 3 and 5 years, but investigators reluctant to say "cure" Sep 10, 2019
'Dirtier' Drugs Step Aside in RET-Positive NSCLC Over two-thirds of patients respond to selective RET inhibitor Sep 09, 2019
TMB in Lung Cancer: 'Not Ready for Prime Time' No association between tumor mutational burden and outcomes in three trials Sep 09, 2019
Small Cancer Risk With Lung Micronodules Supports classifying small nodules as negative scan result Jul 10, 2019
More Clarity to Steroids' Effect on Anti-PD-1 Therapy Adverse effects driven by palliative indications associated with poor prognosis Jun 27, 2019
Rheumatologist's Primer on Checkpoint Inhibitors Specialist reviews the landscape of cancer drugs' autoimmune side effects Apr 09, 2019
Durable Responses With Keytruda in Later-Line SCLC Plus umbralisib in marginal zone lymphoma and a next-generation TRK-targeted agent Apr 04, 2019
MET Inhibitor Rescues Some Targeted Tx Failures in NSCLC Savolitinib promising in patients with MET-based resistance to EGFR inhibition Apr 01, 2019 video
CAR T-Cell Therapy Active in Solid Tumors Preliminary data on safety, efficacy in mesothelioma, sarcomas Mar 31, 2019 video
Aggressive Tx in Oligometastatic NSCLC Tied to Improved OS Histology, intrathoracic disease burden, and bone metastases may predict outcomes Mar 12, 2019
Liquid Biopsy Matches Tissue for NSCLC Guidance Increased mutation detection rate, faster turnaround time Feb 27, 2019
Rapid Heart Rate Tied to Higher Mortality in Cancer Patients Unexplained tachycardia linked with threefold increase in risk of death Jan 28, 2019
Cancer Treatment and Arthritis: A Growing Complaint Will checkpoint inhibitor-related arthritis outstrip RA in frequency? Dec 27, 2018
Increased Risk of Chemo-Associated AML for Nearly All Solid Cancers Extended beyond 5 years for most types with greater risk seen in young patients Dec 20, 2018
Immunotherapy Combo Flops in Metastatic NSCLC Durvalumab plus tremelimumab failed to improve survival versus chemotherapy Dec 13, 2018
Highlights from Molecular Targets Symposiuim Breast cancer gene expression, activity in GI, lung, and limited-mutation tumors Nov 16, 2018
Group of Blood Pressure Drugs Linked to Lung Cancer 14% higher likelihood in users of ACE inhibitors; causal relationship unproven Oct 25, 2018
Hippocampus-Sparing Radiation a New Option in Brain Mets Patients Approach preserved cognitive function, but patient prognosis a key consideration Oct 24, 2018
Aggressive RT, Surgery Doubles OS in NSCLC With Limited Mets If new drug produced such a response it would make "millions," said expert Oct 22, 2018 video
SBRT Doubles 5-Year Survival in Oligometastatic Cancers Most patients in phase II trial had up to three metastatic lesions Oct 17, 2018
Lung Screening Saves Lives, but Who Should Be Screened? Experts debate controversial screening issues in meeting "Smackdown" Oct 11, 2018
Lung Cancer Screening Rates Fall Short in VA Adherence was 77% among those with negative baseline screens Oct 04, 2018
More Evidence that Screening Cuts Lung Cancer Deaths Significantly lower risk in men and women Sep 26, 2018
Newer ALK Inhibitor Tops Standard in NSCLC Significant improvement in PFS with brigatinib after short follow-up Sep 26, 2018
Anti-PD-L1 Drug Boosts Survival in Stage III NSCLC New standard of care for patients with inoperable disease Sep 26, 2018
Add-On Keytruda Boosts OS in Advanced Squamous Lung Cancer Benefit seen across all subgroups, PD-L1 expression levels Sep 25, 2018
No Survival Benefit with Cranial RT for NSCLC Better disease-free survival, fewer brain mets Sep 25, 2018
Nothing Good for Older Lung Cancer Patients From Add-On Cisplatin Two trials show no survival benefit and more toxicity Jul 26, 2018
Surveillance Not Resection Called Best For Subsolid Lung Nodules Opacities tied to increase in lung cancers, but never fatal during a decade of follow-up Jul 25, 2018
Keytruda Alone Bests Chemo in Advanced NSCLC Monotherapy boosts survival in patients with low PD-L1, no EGFR or ALK alterations Jun 04, 2018
